GSA Capital Partners’s West Pharmaceutical WST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-1,413
| Closed | -$465K | – | 2055 |
|
|
2024
Q2 | $465K | Buy |
+1,413
| New | +$499K | 0.03% | 1014 |
|
|
2023
Q1 | – | Sell |
-1,161
| Closed | -$273K | – | 1976 |
|
|
2022
Q4 | $273K | Sell |
1,161
-2,461
| -68% | -$583K | 0.03% | 1001 |
|
|
2022
Q3 | $891K | Buy |
3,622
+87
| +2% | +$26.5K | 0.12% | 211 |
|
|
2022
Q2 | $1.07M | Buy |
+3,535
| New | +$1.15M | 0.16% | 118 |
|
|
2020
Q4 | – | Sell |
-1,495
| Closed | -$411K | – | 1649 |
|
|
2020
Q3 | $411K | Buy |
+1,495
| New | +$396K | 0.07% | 520 |
|
|
2020
Q2 | – | Sell |
-3,091
| Closed | -$471K | – | 1163 |
|
|
2020
Q1 | $471K | Buy |
+3,091
| New | +$476K | 0.12% | 198 |
|
|
2019
Q4 | – | Sell |
-5,004
| Closed | -$710K | – | 1773 |
|
|
2019
Q3 | $710K | Buy |
5,004
+2,045
| +69% | +$282K | 0.1% | 331 |
|
|
2019
Q2 | $370K | Buy |
+2,959
| New | +$349K | 0.04% | 857 |
|
|
2018
Q2 | – | Sell |
-2,761
| Closed | -$244K | – | 1966 |
|
|
2018
Q1 | $244K | Sell |
2,761
-4,207
| -60% | -$394K | 0.01% | 1390 |
|
|
2017
Q4 | $688K | Buy |
6,968
+2,913
| +72% | +$286K | 0.04% | 783 |
|
|
2017
Q3 | $390K | Sell |
4,055
-7,927
| -66% | -$717K | 0.03% | 1108 |
|
|
2017
Q2 | $1.13M | Sell |
11,982
-2,952
| -20% | -$272K | 0.07% | 469 |
|
|
2017
Q1 | $1.22M | Buy |
14,934
+8,000
| +115% | +$669K | 0.07% | 520 |
|
|
2016
Q4 | $588K | Sell |
6,934
-7,963
| -53% | -$626K | 0.04% | 891 |
|
|
2016
Q3 | $1.11M | Sell |
14,897
-837
| -5% | -$66.4K | 0.06% | 555 |
|
|
2016
Q2 | $1.19M | Buy |
+15,734
| New | +$1.15M | 0.07% | 520 |
|
|
2016
Q1 | – | Sell |
-17,134
| Closed | -$1.03M | – | 1945 |
|
|
2015
Q4 | $1.03M | Buy |
17,134
+2,601
| +18% | +$156K | 0.05% | 683 |
|
|
2015
Q3 | $787K | Sell |
14,533
-1,401
| -9% | -$81.6K | 0.04% | 832 |
|
|
2015
Q2 | $925K | Sell |
15,934
-1,300
| -8% | -$72.6K | 0.04% | 969 |
|
|
2015
Q1 | $1.04M | Buy |
17,234
+8,100
| +89% | +$432K | 0.04% | 836 |
|
|
2014
Q4 | $486K | Buy |
9,134
+4,261
| +87% | +$213K | 0.03% | 943 |
|
|
2014
Q3 | $218K | Sell |
4,873
-14,619
| -75% | -$621K | 0.01% | 1476 |
|
|
2014
Q2 | $822K | Sell |
19,492
-237
| -1% | -$10.2K | 0.04% | 792 |
|
|
2014
Q1 | $869K | Buy |
+19,729
| New | +$929K | 0.06% | 417 |
|
|
2013
Q3 | – | Sell |
-8,802
| Closed | -$309K | – | 1681 |
|
|
2013
Q2 | $309K | Buy |
+8,802
| New | +$290K | 0.04% | 854 |
|
Other funds holding WST
GSA Capital Partners's WST Position: Q3 2024 in Review
GSA Capital Partners sold out of West Pharmaceutical (WST) in Q3 2024, closing a stake of 1,413 shares — an estimated $465K sold.
GSA Capital Partners first reported a position in WST in Q2 2013 and held it in 25 quarters. The position peaked at $1.22M in Q1 2017. 730 funds tracked by Wall St. Rank hold WST as of Q3 2024.
- GSA Capital Partners reported no remaining West Pharmaceutical position as of Q3 2024 after selling out during the quarter.
- GSA Capital Partners sold 1,413 West Pharmaceutical shares in Q3 2024, an estimated $465K.
- GSA Capital Partners first reported a position in West Pharmaceutical in Q2 2013 and held it in 25 quarters.
- GSA Capital Partners's West Pharmaceutical position peaked at $1.22M in Q1 2017.
- 730 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2024.
Based on GSA Capital Partners's 13F filing for Q3 2024, filed 5 Nov 2024.